Recent news on Symlin

Amylin Pharmaceuticals to Present at Bank of America Healthcare ...  -  25 May 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Risk-Adverse FDA Is a Risk to the Public  -  May 18, 2007
Wall Street JournalTwo years ago, for example, the RiskMAP that accompanied the FDA's approval of a diabetes drug called Symlin prohibited the company from conducting

Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders  -  May 18, 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Drug Safety Proposals and the Intrusion Of Federal Regulation into ...  -  May 11, 2007
American Enterprise Institute,Symlin example. One recent example that overstepped the traditional use of RiskMaps was the risk-management plan promulgated with the approval of the

Amylin plant to create up to 600 jobs  -  May 3, 2007
Cincinnati Post,Amylin, which produces the diabetes medications Symlin and Byetta, will create 500 to 600 jobs with average annual salaries of $50000, said Butler County

West Chester biotech firm building packaging plant  -  May 2, 2007
Dayton Daily News (subscription),Amylin, which produces diabetes medications Symlin and Byetta, will invest up to $600 million in the new facility, Butler County Commissioner Mike Fox said.

Amylin Pharmaceuticals Reports First Quarter Financial Results  -  Apr 16, 2007
PR-Inside.com (Pressemitteilung),..."BYETTA and SYMLIN, our two first-in-class medicines for diabetes, continue to grow in an expanding market. Exenatide LAR and our other pipeline programs

Smaller loss boosts Amylin's shares  -  Apr 17, 2007
San Diego Union Tribune,Sales of Symlin, for the treatment of type 1 diabetes, were $15.5 million last quarter, up from $7.6 million a year earlier.

Amylin posts smaller loss, higher drug sales  -  Apr 16, 2007
ReutersSales of another diabetes injection called Symlin also doubled to $15.5 million. Amylin shares were up $1.92, or 4.8 percent, at $41.93 in morning Nasdaq

Amylin Pharmaceuticals Narrows 1Q Loss  -  Apr 16, 2007
Houston Chronicle,Amylin reported sales of $162 million during the quarter, which included $146.5 million for its Byetta injections and $15.5 million for its Symlin injection

Friday's Health Winners & Losers  -  Apr 13, 2007
TheStreet.comShares of Amylin Pharmaceuticals (AMLN - Cramer's Take - Stockpickr), the maker of the diabetes drugs Symlin and Byetta, were also higher after Lazard

Amylin Pharmaceuticals to Webcast First Quarter Results  -  Apr 9, 2007
Genetic Engineering News (press release),Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

New Test Assesses Average After-Meal Glucose Spikes  -  Apr 2, 2007
Diabetes Health (press release),In fact, reducing after-meal glucose rises is a goal of many of the new medicines out there, including fast-acting insulins, Byetta, Symlin, and others.

Pharmaceutical firm plans big investment in region  -  Mar 27, 2007
Middletown Journal,Two drugs Amylin produces — Symlin, a meal-time insulin injection, and Byetta, a twice-daily injection for long-term blood sugar control — received FDA

Zacks Analyst Blog Highlights: Philips Electronics, Skyworks ...  -  Apr 17, 2007
Business Wire (press release),The top-line is being driven by sales of two diabetes drugs, Byetta and Symlin. Sales of both drugs were lower than expected in the most recent quarter due

The drug Exubera looks like an expensive flop for Pfizer  -  Apr 10, 2007
International Herald Tribune,In the last two years, three new diabetes medicines have reached the market - Januvia, Byetta and Symlin - as well as Levemir, a longer-acting version of

$2.5 MILLION AWARDED TO HIGH TECHNOLOGY COMPANIES Third Frontier ...  -  Mar 28, 2007
ODOD (press release),Amylin has developed and gained approval for two first-in-class medicines to treat diabetes, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate)

A triumphant exit  -  Mar 7, 2007
San Diego Union Tribune,Then, on the December 2003 day when the company expected to hear that Symlin had been approved, nothing happened. And the next day, Amylin received a letter

Prescription for Trouble  -  Mar 5, 2007
Wall Street Journal (subscription),Consider the RiskMAP recently imposed by the FDA on the use of the diabetes drug Symlin. The new medicine can help very serious diabetics control swings in

Amylin Pharmaceuticals to Present at Lehman Brothers Global ...  -  Mar 14, 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Nasdaq 100 Leaders & Laggards: SIRI KLAC  -  Mar 5, 2007
Forbes,AMLN - news - people ) advanced 39 cents to $36.80 after Wall Street analysts said demand for the company's diabetes drugs Byetta and Symlin is growing.

Midday Leaders & Laggards: Nasdaq 100  -  Mar 5, 2007
Forbes,...news - people ) added 96, or 2.6 percent, to $37.37 after Wall Street analysts said demand for the company's diabetes drugs Byetta and Symlin is growing.

Amylin Pharmaceuticals Reports 2006 Financial Results  -  Feb 1, 2007
Drug Newswire (press release),..."The acceptance in the diabetes community for our two first-in-class medicines, BYETTA and SYMLIN, continues to grow and our research pipeline shows great

Amylin Pharmaceuticals Announces Appointment of Daniel M. Bradbury ...  -  Jan 31, 2007
PharmaLive.com (press release),..."BYETTA and SYMLIN are well-positioned to drive the company's near-term growth, and the long-acting formulation of BYETTA in development provides tremendous

New Medicines For Diabetics  -  Feb 4, 2007
Wheeling News Register,During the meeting, Bonyak will educate people about three new medicines — Byetta, Januvia and Symlin, which are expected to be possible alternatives to

Amylin 4Q Loss Narrows on Sales Surge  -  Jan 30, 2007
Forbes,Amylin, which makes the diabetes drugs Byetta and Symlin, reported a loss of $58.4 million, or 45 cents per share, including 11 cents per share for

Loss Narrows at Amylin  -  Jan 30, 2007
TheStreet.comByetta accounted for $137 million of fourth-quarter sales, Symlin contributed $13.6 million and money from collaborations accounted for the rest.

No Sickness For Amylin  -  Jan 31, 2007
Motley FoolRevenue for the quarter, primarily from sales of its type 2 diabetes treatments Byetta and Symlin, jumped over 160% year over year to $150 million.

Amylin Pharmaceuticals to Present at Merrill Lynch Global ...  -  Feb 1, 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Biotech Starts Out on Right Foot in January  -  Feb 1, 2007
CNW Telbec (Communiqués de presse),Amylin Pharmaceuticals Inc.'s closed up 8% after reporting its fourth-quarter loss narrowed as sales of its two diabetes drugs -- Byetta and Symlin

Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference  -  Jan 3, 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Guest essay: New medications can help those with diabetes  -  Nov 29, 2006
Chambersburg Public Opinion,The second groundbreaking medication is Symlin, which assists with glucose control after meals and suppresses appetite. Symlin is recommended for

Ginger Graham leads Amylin to enviable market position  -  Dec 5, 2006
MarketWatchThe benefits of Symlin and Byetta were still in question when Graham took over from Joe Cook, another Eli Lilly alum and Amylin's current chairman,

Commentary: Price Is Too High For Drug Cost Controls  -  Dec 7, 2006
Evening Bulletin,But the really big miracle for me was a new drug: Symlin (a synthetic version of the hormone amylin), which I inject along with insulin three times a day.

Medical Edge: Care pays off for diabetics  -  Dec 2, 2006
Bryan College Station Eagle,Called pramlintide (Symlin), it is a protein that, in healthy people, is secreted by the pancreas along with insulin. This protein is missing in type 1

FDA Approves BYETTA(R) (exenatide) Injection for Expanded ...  -  Dec 22, 2006
PR Newswire (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals to Present at BIOCOM Investor Conference ...  09 Nov 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide ... -Yahoo! News (press release) A little biotech's big, risky bet on weight loss  Nov 4, 2006
Amylin (Charts) is experimenting with its injectable drug Symlin, which is already on the market to control blood sugar levels for diabetics, for an additional ... -CNNMoney.com Amylin Pharmaceuticals Reports Third Quarter Financial Results  Oct 18, 2006
..."Adoption of our two first-in-class medicines, BYETTA and SYMLIN, by patients and healthcare professionals continues to grow," said Ginger L. Graham, Chief ... -MSN Money Amylin Pharmaceuticals Expands Clinical Program In Obesity  Oct 25, 2006
Amylin Pharmaceuticals. "This approach has been applied successfully to diabetes with the introduction of BYETTA and SYMLIN. Today ... -Medical News Today (press release), Amylin Narrows Losses  Oct 18, 2006
...quarter results Oct. 18. The firm continues to improve its bottom line as sales from Byetta and Symlin increase. Compared with the ... -San Diego Business Journal, Amylin 3Q Loss Narrows on Byetta Sales  Oct 18, 2006
The jump came from sales of the diabetes drugs Byetta and Symlin. ... are partners on Byetta. Symlin sales made up $12.4 million of Amylin's revenue. ... -Houston Chronicle, Amylin Pharmaceuticals (AMLN) Reports Q3 Loss  Oct 18, 2006
CEO Ginger L. Graham said, "Adoption of our two first-in-class medicines, BYETTA and SYMLIN, by patients and healthcare professionals continues to grow. ... -StreetInsider.com (subscription), UPDATE 1-Amylin Pharmaceuticals 3rd-quarter loss narrows  Oct 18, 2006
The company's only other marketed drug, called Symlin and also launched last year as an injectable treatment for type 2 diabetes, had third-quarter sales of ... -Reuters Amylin Expands Trials for Obesity Drug  Oct 25, 2006
...drugs is a new development for the company, which has seen a great deal of growth in the past year after the FDA approved diabetes drugs Symlin and Byetta in ... -Red Herring, Foro de Shell Security - Seguridad informática  Oct 26, 2006
...bone marrow is devoid of hem sustiva On morphologic evaluation, the bone marrow is d symbyax void of hematopoietic elements, showing largely symlin fat cells. ... -Shell Security, Diabetes Drug Company Plans to Press on With Trials of Pramlintide ...  Oct 25, 2006
L. Graham. "This approach has been applied successfully to diabetes with the introduction of Byetta and Symlin," he said. "Today ... -Diet Drug Report, Winning life's pageant and living well with diabetes  Oct 24, 2006
...for blood. Injections of Symlin, a hormone that makes the body use insulin more efficiently, have improved her control. She's now ... -Pittsburgh Post Gazette, Byetta Boosts Amylin's Sales  Oct 18, 2006
...the drug. Another diabetes treatment, Symlin, which Amylin markets by itself, produced third-quarter sales of $12.4 million. The ... -TheStreet.com Pharma Earnings On Tap-Upcoming Week In Earnings  Oct 17, 2006
In early September, the company reported positive results from a 16-week study of adding SYMLIN to an established regimen of basal insulin glargine in patients ... -Trading Markets, Monster of a cure  Oct 17, 2006
She said Byetta reduces food intake and slows gastric intake for Type 2 diabetics and Symlin treats Type 1 diabetes and is a synthetic form of the human ... -Hattiesburg American, Amylin Pharmaceuticals to Present at UBS Warburg Global Life ...  Sep 22, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide ... -PR Newswire

Amylin says Symlin, insulin regimen helps glucose control  Sep 7, 2006
Amylin Pharmaceuticals Inc. (AMLN) said adding Symlin to a regimen of basal insulin for patients with type 2 diabetes reported better overall glucose control ... -MarketWatch

Amylin Sees Positive Results on Symlin  Sep 7, 2006
...said Thursday a study showed adding Symlin, a synthetic analog of the human hormone amylin, to type 2 diabetes patients' insulin regimen improved glucose ... -MSN Money

Amylin Pharma Says SYMLIN Improved Diabetes Control In Patients On ...  Sep 7, 2006
...(AMLN | charts | news | PowerRating) announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN® (pramlintide acetate ... -Trading Markets

SYMLIN Improved Diabetes Control In Patients With Type 2 Diabetes ...  Sep 8, 2006
...(Nasdaq: AMLN) today announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN(R) (pramlintide acetate) to an ... -Medical News Today

SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes ...  Sep 8, 2006
Today announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN(R) (pramlintide acetate) to an established regimen of ... -PipelineReview.com

NutraCea to Present at Roth Capital Growth Conference and ...  Sep 11, 2006
...(Nasdaq: AMLN) recently announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN® (pramlintide acetate) to an ... -Financial News USA

NEWS RELEASE  Sep 8, 2006
Biopharmaceutical company Amylin Pharmaceuticals Inc. (Nasdaq:AMLN) said Thursday a study showed adding Symlin, a synthetic analog of the human hormone amylin ... -Financial News USA

Daily Digest  Sep 7, 2006
Amylin Pharmaceuticals Inc. announced positive results from a 16-week study evaluating the safety and efficacy of its drug Symlin, and Wireless Facilities Inc. ... -San Diego Daily Transcript (subscription)

(PRN) - Discovery Communications Announces Roger F. Millay as ...  Sep 7, 2006
Flow ... [+. PRN) - SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin ... [+. ... -Bolsamania.com

Ginger Graham leads Amylin to enviable market position  -  Dec 5, 2006
MarketWatchThe benefits of Symlin and Byetta were still in question when Graham took over from Joe Cook, another Eli Lilly alum and Amylin's current chairman,

Commentary: Price Is Too High For Drug Cost Controls  -  Dec 7, 2006
Evening Bulletin,But the really big miracle for me was a new drug: Symlin (a synthetic version of the hormone amylin), which I inject along with insulin three times a day.

Guest essay: New medications can help those with diabetes  -  Nov 29, 2006
Chambersburg Public Opinion,The second groundbreaking medication is Symlin, which assists with glucose control after meals and suppresses appetite. Symlin is recommended for

Medical Edge: Care pays off for diabetics  -  Dec 2, 2006
Bryan College Station Eagle,Called pramlintide (Symlin), it is a protein that, in healthy people, is secreted by the pancreas along with insulin. This protein is missing in type 1

Analysis: Analysts mixed on Amylin  -  Nov 21, 2006
United Press InternationalAmylin's obesity pipeline is promising, but phase 2 data for Symlin, which is scheduled to be released in the second half of 2007, will provide a more

Amylin Pharmaceuticals to Present at Piper Jaffray Healthcare ...  -  Nov 24, 2006
Genetic Engineering News (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals, Inc. Announces Conversion of All ...  Aug 24, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide ... -American Digital Networks

Amylin's Amazing Run Still Has Steam  Aug 2, 2006
The US Food and Drug Administration approved Byetta (exenatide) and Symlin (pramlintide acetate) in the spring of 2005, and both injectable drugs are beginning ... -Forbes

Amylin Exec Meets With Tony Blair  Aug 1, 2006
...dozen executives. Among them was Bradbury from San Diego’s Amylin, which sells two diabetes drugs, Byetta and Symlin. Also present ... -San Diego Business Journal

Manhattan Research Reveals Top Pharmaceutical Websites Visited by ...  Aug 2, 2006
Ebritux, Abilify, Novolog, Levaquin, Flomax, Herceptin, Nasonex, Clarinex, Copaxone, Seasonale, Patanol, Viread, Keppra, Lupron, Oxytrol, Symlin, Byetta, Avonex ... -Yahoo! News

Earnings Preview: Amylin Pharmaceuticals  Jul 21, 2006
Also, the company's Symlin, an anti hyperglycemic drug used in diabetic patients treated with insulin, is expected to pick up sales. ... -Houston Chronicle



Amylin Pharmaceuticals Reports First Quarter Financial Results  Apr 26, 2006
..."The physician and patient demand for our two first-in-class products, BYETTA and SYMLIN, continues to increase, and has resulted in strong revenue growth in ... - PR Newswire

Amylin Pharmaceuticals Reports First Quarter Financial Results  Apr 26, 2006
..."The physician and patient demand for our two first-in-class products, BYETTA and SYMLIN, continues to increase, and has resulted in strong revenue growth in ... - PharmaLive.com





Research and Markets: Amylin's Pramlintide Acetate (Symlin) ...  Mar 27, 2006
Amylin's pramlintide acetate (Symlin) recently received approval as an adjunct therapy in combination with insulin for patients with type 1 diabetes. ... - International News Service

Amylin to Sell 9.8M Shares  Mar 27, 2006
Amylin also has another approved injectable diabetes drug, Symlin. Both Symlin and Byetta were the first drugs approved in their ... - Red Herring

Biotech progress overlooked  Apr 8, 2006
New drugs approved this year include Onyx Pharmaceuticals Inc.'s and Bayer AG's Nexavar cancer medicine and Amylin Pharmaceutical Inc.'s Symlin and Byetta ... - Arizona Republic

Hedge fund operator gets prison  Mar 11, 2006
The terms weren't disclosed. Amylin Pharmaceuticals said it raised the prices of its diabetes drugs, Byetta and Symlin injections. ... - San Diego Union Tribune

Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes ...  Mar 24, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(TM) (exenatide ... - Finanzen.net

William Blair & Company Initiates Coverage of Amylin ...  Mar 21, 2006
..."The combination of two first-in-class FDA-approved drugs (Byetta and Symlin), strong management, significant pipeline growth potential, a strong balance sheet ... - PR Newswire



Amylin Weight-Loss Drug Shows Promise in Early Trial  Feb 8, 2006
It is same drug as Symlin, which the US Food and Drug Administration earlier this year gave Amylin approval to sell as a therapy for people with type 1 and ... - Diet Drug Report,

Stock Strategist: Biotech Investing for the Long Haul  Feb 22, 2006
New types of diabetes drugs, such as Pfizer's and Nektar's inhaled insulin Exubera and Amylin's non-insulin injectable drugs Symlin and Byetta, give patients ... - TMCnet

Drug firm welcomed to West Chester  Feb 6, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes: Symlin (pramlintide acetate) injection and Byetta (exenatide) injection ... - Cincinnati Business Courier,

Some Weighty Issues Face Firms That Eye New Obesity Drugs  Feb 3, 2006
50% since June. Amylin also is trying to develop YY3-36 and looks to adapt its Symlin diabetes drug to obesity therapy. Search for ... - Investor's Business Daily (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional